Greatmark Investment Partners Inc. Buys 1,845 Shares of Elevance Health, Inc. $ELV

Greatmark Investment Partners Inc. boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 5.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,622 shares of the company’s stock after purchasing an additional 1,845 shares during the quarter. Elevance Health accounts for approximately 1.3% of Greatmark Investment Partners Inc.’s holdings, making the stock its 23rd biggest position. Greatmark Investment Partners Inc.’s holdings in Elevance Health were worth $11,306,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Kemnay Advisory Services Inc. acquired a new stake in Elevance Health in the 4th quarter worth $31,000. J.Safra Asset Management Corp acquired a new position in shares of Elevance Health during the fourth quarter valued at about $32,000. ORG Partners LLC lifted its stake in shares of Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after buying an additional 59 shares during the period. Dorato Capital Management bought a new stake in shares of Elevance Health in the fourth quarter valued at about $41,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Elevance Health during the fourth quarter worth about $38,000. 89.24% of the stock is owned by institutional investors.

Insider Activity at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the sale, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.34% of the stock is owned by company insiders.

Elevance Health Stock Performance

NYSE ELV opened at $408.35 on Tuesday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $427.19. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $88.68 billion, a P/E ratio of 17.37, a PEG ratio of 2.37 and a beta of 0.67. The company’s 50-day simple moving average is $391.29 and its 200 day simple moving average is $351.07.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter last year, the company earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, research analysts forecast that Elevance Health, Inc. will post 26.86 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date was Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Morgan Stanley boosted their price target on Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a research note on Thursday, June 4th. Leerink Partners set a $364.00 price objective on Elevance Health in a research report on Thursday, April 23rd. Jefferies Financial Group decreased their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Barclays boosted their price objective on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. Finally, Citigroup upgraded Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Fifteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $420.70.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.